2LBA LBA Oral - Immune subtyping in the Response Predictive Subtypes (RPS) identifies a subset of triple negative (TN) early-stage breast cancer patients with a very low likelihood of response to neoadjuvant immunotherapy (IO): results from 5 IO arms of the I-SPY2 TRIAL

Authors :: Wolf, D.M.
Yau, C.
Haan, J.
Wehkamp, D.
Witteveen, A.
Glas, A.
Campbell, M.
Nanda, R.
Chien, J.
Shatsky, R.
Isaacs, C.
Barcura, A.
Mittempergher, L.
Kuilman, M.
Yee, D.
DeMichele, A.
Perlmutter, J.
Pusztai, L.
Esserman, L.
van 't Veer, L.J.
Source :: European Journal of Cancer. Mar2024:Supplement 1, Vol. 200, pN.PAG-N.PAG. 1p.
Publication Year :: 2024

Subjects :: *BREAST cancer prognosis
*IMMUNOPHENOTYPING
*BREAST tumors
*IMMUNOTHERAPY
*TREATMENT effectiveness
*CONFERENCES & conventions
*COMBINED modality therapy

Full Text Access

Tools